An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
CytRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
CytRx Corporation (OTCQB: CYTR) has announced that CEO Steven A. Kriegsman will present at the H.C. Wainwright 23rd Annual Global Investment Conference, held virtually from September 13-15, 2021. The presentation will highlight CytRx's promising pipeline, including licensing agreements with ImmunityBio and Orphazyme. Key topics include the Centurion BioPharma subsidiary and the innovative LADR™ Platform, designed to enhance drug delivery while reducing toxicity. The presentation will be accessible on-demand starting September 13.
Positive
None.
Negative
None.
LOS ANGELES--(BUSINESS WIRE)--
CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, the Company’s Chairman and Chief Executive Officer, is scheduled to present at the H.C. Wainwright 23rd Annual Global Investment Conference, which is taking place virtually September 13-15, 2021.
Mr. Kriegsman's presentation will focus on CytRx’s high-potential pipeline and assets, including its licensing agreements with ImmunityBio, Inc. and Orphazyme A/S. The presentation will also discuss the Company’s assessment of its Centurion BioPharma subsidiary and its LADR™ Platform, which aims to concentrate ultra-high-potency drugs in solid tumors and minimize systemic toxicity. In addition to the LADR™ Platform, the technology includes the ACDx diagnostic, which was developed to allow oncologists to determine which patients can benefit from the ultra-high-potency drugs.
The virtual presentation will be available for on-demand access at this link and on CytRx's website under the News & Events section beginning the week of September 13th.
About CytRx Corporation
CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx’s most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, CytRx’s drug candidate, arimoclomol, was sold to Orphazyme A/S in exchange for milestone payments and royalties. Orphazyme is developing arimoclomol in two indications, including Niemann-Pick disease Type C (NPC), and Gaucher disease. CytRx Corporation’s website is www.cytrx.com.
When will CytRx present at the H.C. Wainwright Annual Global Investment Conference?
CytRx will present at the conference virtually from September 13-15, 2021.
Who is presenting for CytRx at the investment conference?
Steven A. Kriegsman, the Chairman and CEO of CytRx, will be presenting.
What will be discussed during CytRx's presentation?
The presentation will cover CytRx's pipeline, licensing agreements with ImmunityBio and Orphazyme, the Centurion BioPharma subsidiary, and the LADR™ Platform.
Where can I watch the CytRx presentation?
The presentation will be available for on-demand access on CytRx's website starting the week of September 13.
What is the LADR™ Platform mentioned by CytRx?
The LADR™ Platform aims to deliver ultra-high-potency drugs to solid tumors while minimizing systemic toxicity.
